3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
8
Polycystic Ovary Syndrome
5
Multiple Myeloma
5
Prostatic Neoplasms
4
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Pancreatic Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Carcinoma In Situ
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Venous Thromboembolism
1
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Thrombosis
1
Smoldering Multiple Myeloma
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Rectal Neoplasms
1
Perioperative Inflammatory Response
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neurotoxicity Syndromes
1
Interventions
Sirolimus
9
Everolimus
3
Imatinib Mesylate
2
temsirolimus
1
saracatinib
1
nintedanib
1
carbon-11 acetate
1
Valproic Acid
1
Urination
1
Sugars
1
Simvastatin
1
Resveratrol
1
Respiratory Function Tests
1
Phlebotomy
1
Loratadine
1
Letrozole
1
Immunoglobulin G
1
Hydroxychloroquine
1
Glutamine
1
Genetic Testing
1
Doxycycline
1
Disulfides
1
Cetuximab
1
Celecoxib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphangioleiomyomatosis
×
Simvastatin
×
Clear all
NCT02061397
2020-08-25
SOS
University of Pennsylvania
Phase 1/2
Completed
10 enrolled
6 charts